Disease Detail

ID DOID:3119
Name gastrointestinal system cancer
Definition An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system.
Source DiseaseOntology.org
Alt Ids DOID:4945 DOID:8377
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Axitinib + Fluorouracil + Irinotecan + Leucovorin gastrointestinal system cancer not applicable detail...
Unknown unknown Cabozantinib gastrointestinal system cancer not applicable detail...
ERBB2 amp Dacomitinib gastrointestinal system cancer sensitive detail...
Unknown unknown Apatinib gastrointestinal system cancer not applicable detail...
Unknown unknown Axitinib + Fluorouracil + Leucovorin + Oxaliplatin gastrointestinal system cancer not applicable detail...
Unknown unknown Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin gastrointestinal system cancer not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Epirubicin + Fluorouracil gastrointestinal system cancer not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Irinotecan gastrointestinal system cancer decreased response detail...
Unknown unknown PX-12 gastrointestinal system cancer no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01640665 Phase I Capecitabine + Sorafenib Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Completed
NCT01916447 Phase I Bevacizumab trifluridine/tipiracil hydrochloride Irinotecan A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. Completed
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated
NCT02319018 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Alisertib Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors Completed
NCT02344810 Phase Ib/II AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn
NCT02417753 Phase II AZD9150 AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites Terminated
NCT02757391 Phase I Aldesleukin + Cyclophosphamide + Pembrolizumab T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies Not yet recruiting
NCT03065387 Phase I Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib Study of the Pan-ERBB InhibStudy of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation Recruiting
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Not yet recruiting